Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy

NCT00742482 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
418
Enrollment
INDUSTRY
Sponsor class

Stopped A 300 patient safety analysis by the Data Monitoring Committee showed a trend towards higher mortality in the treatment group.

Conditions

Interventions

Sponsor

LEO Pharma